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• Abstract: Exosomes are nanovesicles secreted by many cells, including cancer cells.  Extensive 
research has been carried out to validate potential applications of exosomes and to evaluate 
their efficiency in a wide range of diseases, including cancer. The current knowledge on the 
origin, biogenesis and composition of exosomes is described. This review then focusses on the 
use of exosomes in cancer diagnostics and therapeutics.  
• Graphical abstract: 
• Keywords: Exosomes, cancer, miRNA, progression, therapeutic, diagnostic, nucleic acid, 
angiogenesis, immunosuppression, immune system.
• Main body of text: Introduction
A revolutionary communication system between cells has recently been discovered that utilises 
nanoparticles, named exosomes, to send encrypted/encoded messages across the human body. 
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Exosomes (30-100nm) are classified as one of the extracellular vesicles (EVs) that are secreted by most 
mammalian cell types and found circulating in body fluids, such as urine, blood, saliva, seminal fluid and 
cerebrospinal fluid [1]. Under normal conditions, exosomes are secreted to maintain normal 
physiological conditions/functions. While in response to pathological conditions, exosomes are found to 
be secreted in high numbers. Scientists have exerted extensive efforts to understand their purpose in a 
range of diseases. The focus of this review is to examine the role that cancer cell-derived exosomes have 
in disease progression, diagnostics, prognosis assessment and therapeutic approaches in fighting cancer. 
In terms of cancer progression, the disease is initiated through cell-cell communication between cancer 
cells and their neighbouring cancerous and non-cancerous cells, mediated via exosomes [2,3]. Exosomes 
are carriers of genetic information and signalling molecules that can control processes such as 
angiogenesis, metastasis and chemotherapeutic resistance. Hence understanding the role of exosomes 
in these processes can help to develop therapeutics that can manipulate and control the pathways in an 
effort to halt disease progression. 
In cancer diagnosis, exosomes provide a safe and cost-effective way of determining disease progression 
and prognosis. The reason for this is that exosome samples can simply be collected by liquid biopsy from 
body fluids. This is advantageous unlike traditional cancer tissue biopsy that involves an invasive process 
and a requirement for healing time of tissues that can take several weeks to months. Since analysis of 
exosomes provides fast accessibility to biological information of affected tissues and organs, it also has a 
growing and important role in understanding, monitoring and enabling personalised treatment of 
cancer.  
Collectively, the knowledge gained in these areas together with understanding exosome structure and 
composition can be utilized to create exosome mimetics that are capable of delivering a desirable 
therapeutic solution. These exosomes can be manipulated, re-engineered, encapsulated, and decorated 
for therapeutic purposes due to their stability, loading capacity and flexibility [4]. Therefore, exosomes 
play a versatile role as nanovesicles in therapeutic drug delivery and are likely to have significant impact 
in future cancer therapeutic approaches.
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The late 1960s saw the publication of research where a concentrated matrix of vesicles was found in 
cartilage tissue that was shown to induce calcification in the epiphysis of long bones [5]. These EVs were 
also discovered in biological fluids, such as blood and semen [6,7]. In the 1980s, it was revealed that the 
EVs secretion process was complex, starting with the formation of vesicles inside late endosomes (LEs) 
or multivesicular bodies (MVBs) which could be released into the extracellular environment [8,9]. 
Subsequently, two research groups investigating reticulocyte maturation reported their observations on 
tiny vesicles being released into the extracellular space during reticulocyte differentiation [10]. By 1987, 
the term “exosome” was used for the first time to describe these tiny membrane vesicles that formed 
within intracellular endosomes and were released into the extracellular space by exocytosis [11]. 2. Exosome biogenesis 
In the endo-lysosomal system, the formation of endosomes starts with invagination of the membrane, 
to sort the early endosomes (EEs). The content of EEs is mainly derived from the plasma membrane 
during the sorting process of endosomes. Subsequently, EEs mature into LEs. During the maturation 
process, a high number of Intraluminal vesicles (ILVs) are formed in LEs. Hence LEs are commonly named 
MVBs (Figure 1) [12,13]. The biogenesis  of exosomes is starting during the formation of ILVs which is 
thought to be driven by CD9 and CD63 tetraspanins and the endosomal sorting complexes required for 
transport (ESCRT) [14,15].
ESCRT are made up of four multimeric protein units: ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III. Generally, 
they work collectively in this subunit machinery in a unique way to deform membranes surrounding the 
endosome through particular interactions [16]. Briefly, ESCRT-0 is used to cluster cargo through, in a 
ubiquitin-dependent manner. ESCRT-I and ESCRT-II both stimulate budding and ESCRT-III induces vesicle 
splitting. In addition, there are accessory proteins that contribute to the ESCRT machinery, which are the 
VPS4 ATPase, TSG101 and ALIX. VPS4 ATPase has a role in dissociating and recycling the ESCRT complex, 
to assist in the final stages of ILV formation [14]. It has been found that the removal of ESCRT-0 
associated proteins Hrs and TSG101, and STAMI protein of ESCRT-I decrease exosome secretion. 
Furthermore, the suppression of associated proteins of ESCRT-III such as CHMP4C, VPS4B, VTA1 and 
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ALIX results in an increase in exosome production. Therefore, the presence and the absence of these 
accessory proteins plays a critical role in exosome secretion and biogenesis [17].
Figure 1: Biogenesis and secretion of exosomes.2.1 ESCRTs and sorting exosomal cargo 
The ESCRTs complexes were found also to be involved in sorting exosomal cargo rather than exosomes 
biogenesis, through ubiquitinating the endosomal cargo using ubiquitin-binding proteins such as 
hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), signal transducing adaptor molecule 
(STAM) and tumour susceptibility gene 101 (Tsg101) during the endocytic pathway. As part of the 
maturation process of EEs to LEs (MVBs), de-ubiquitinating enzymes were secreted to remove ubiquitin 
from MVBs cargo prior to ILVs formation. [18,19]. 
However, exosomes are still containing ubiquitinated proteins [20]. For instance, Y-box1 (YB-1) is an RNA 
binding protein, was ubiquitinated through HACE1 gene that polyubiquitinates YB-1 and responsible for 
its interaction with Tsg101. This process is required to mediate the secretion of YB-1 containing 
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exosomes [21]. A recent study is performed by Shurtleff et al. on YB-1, it has been revealed that YB-1 
protein play a significant role in sorting microRNAs into exosomes [22]. Hence, several therapeutic 
approaches can be applied using YB-1 as regulatory protein in cancer suppression and sorting specific 
therapeutic microRNAs.  
However, the involvement of ubiquitin in sorting exosomal cargo is still unclear [19]. For instance, the 
expression of MHCII molecules on exosomes surface released from antigen presenting cells (APCs) is not 
ubiquitin dependent, but it was considered  that  MHC II sorted into exosomes by its incorporation into 
tetraspanin CD9 containing detergent resistant membrane [23]. 
Furthermore, another post-translational modification (PTM) has been involved in sorting exosomal 
cargo rather than ubiquitination, is binding to a small ubiquitin-related modifier (SUMO) in a process 
known as SUMOylation [24]. For example, α-Synuclein is an extracellular protein found in the central 
nervous system and involved in Parkinson’s Disease pathology. It has been found that α-Synuclein was 
sorted into extracellular vesicles via SUMOylation [25].
Alix and Tsg101 are ESCRT proteins were found to be directly contributing in recruiting exosomal cargo 
[19]. For instance, Alix was found to be promoting the sorting of Transferrin receptor into exosomes in 
rat reticulocytes [26]. Whereas in human liver stem‑like cells (HLSCs), it has been demonstrated that Alix 
play a significant role in sorting microRNA into EVs through its binding to Argonaute2, an RNA binding 
protein [27].  
Tsg101, was found to be binding Small Integral Membrane Protein of the lysosome/Late Endosome 
(SIMPLE), a Charcot-Marie-Tooth disease causing factor, and induce its exosome subsequent secretion 
[28]
3. Structure and Composition of Exosomes
Due to the extensive investigation and increasing interest in exosomes and EV structure and 
composition, two databases were developed to co-ordinate efforts on the characterization and 
identification of their structure and content.  EV structure characterization is summarized in the 
Vesiclepedia database (http://microvesicles.org). While proteomic and genetic information of exosome 
content, are collated in ExoCarta (http://www.exocarta.org), which is a regularly updated database [29–
31]. A summary of the key components of exosomes are described below. 
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3.1.1 Prostaglandins and Lysophophatidic Acid 
Exosomes were found to be enriched with many lipids such as prostaglandins which are known for their 
role as cell signalling mediators. Another important lipid is lysobisphosphatidic acid (LBPA) which is 
considered an exosomal lipid that has been found abundantly in MVBs internal membranes. Also, LBPA 
and ALIX were found to play a role in internal vesicle budding to form ILVs within MVBs which 
consequently contribute to the process of exosomes production. Moreover, lower LBPA levels results in 
lower numbers of ILVs formati n within MVBs [32].
3.1.2 Plasma Membrane Lipids
The exosome lipid bilayer is mainly composed of plasma membrane lipids such as sphingomyelin (SM), 
phosphatidyl-ethanolamine (PE), phosphatidylserine (PS), ganglioside GM3 and phosphatidylinositol (PI) 
[33]. Recently, these lipids were found to be asymmetrically distributed in the exosome bilayer 
membrane. For instance, SM and other sphingolipids are expected to be allocated in the outer layer, 
while the other lipid classes are mainly distributed in the inner layer. This asymmetrical distribution of 
lipid classes can be changed under the influence of different enzymes such as flippases, floppasses and 
scramblases [34]. The presence of these lipids varies depending on the origin of the exosomes. For 
instance, reticulocytes contain phosphatidylcholine (PC), forming half of the exosomes’ lipids [35]. While 
exosomes originating from mast cells and DCs, consist of less than one third of PC in their overall lipid 
content [36].  
SM, cholesterol (chol), GM3 and PS are also incorporated in synthetic liposomal drug delivery systems. 
For instance, hydrogen bonds formed between SM and chol leads to strongly packed bilayers, and 
decreases the permeability of the membrane to water [37,38]. Additionally, these lipids are insoluble at 
4⁰C in non-ionic detergents such as Triton X, due to their long and saturated chains, which are classified 
as the main constituents of resistant membranes to non-ionic detergents [39]. Hence, these lipids are 
used in exosome mimetics to provide rigidity and stability. Furthermore, a longer circulation time has 
been demonstrated in liposomes, containing SM/chol. Moreover, these lipids decrease inclusion of 
plasma proteins into their membranes [40].
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GM3 has a stabilization effect on the wall of exosomes, and a protection effect that prevents 
interactions between vesicles and blood constituents. Gangliosides, SM and chol act as units to reduce 
liposomal uptake by the reticuloendothelial system both in vitro and in vivo [41]. With high 
concentrations of dipalmitoylphosphatidylglycerol (DPPG)/GM3 (>15 mol%), membrane decomposition 
and vesicle leakage are both induced by high concentrations of GM3 [42]. Therefore, to achieve the 
benefits of GM3, they have to be used in low concentrations in exosome mimetics [41]. 
The role of PS in cell membranes has not been fully established. However, it acts as a signalling molecule 
in several biological processes such as protein C kinase pathways and protein localisation [43]. 
Therefore, the function of PS may vary according to the population of vesicles and cellular sources. For 
instance, mature red blood cells circulating the body continuously express PS externally during the aging 
process, which in turn provides an “eat-me” signal, that induces phagocytosis [44]. 
Extracellular pH also has an effect on vesicle rigidity. In acidic conditions, vesicles contain SM and GM3 
in high concentrations, compared with those lipids represented in normal concentrations at 
physiological (buffered) pH conditions [45]. Hence, at physiological pH, the fusion of exosome 
membranes into target cells are thought to be enhanced [41].
3.2 Proteins
Exosome-associated proteins are involved in regulatory processes and induce cellular responses. 
Exosomal proteins play a functional role in inhibiting interactions with extracellular components and 
facilitate entry to target cells. For instance, it has been observed that proteins cross-linked by 
paraformaldehyde, lower the ability of exosomes to fuse into their parent cells by nearly 20% [45]. 
Furthermore, when these exosomes are solubilised by octylglucoside and dialysis used to reconstitute 
them (to remove membrane proteins), a gradual reduction in exosome ability to fuse into target cells, 
compared to untreated ones has been demonstrated. This represents the effect of proteins on fusion 
efficiency of exosomes [45]. By referring to the ExoCarta database, many of the proteins reported 
include heat shock proteins, annexins and Ras-associated binding (Rab) family proteins. These proteins 
are involved in intracellular exosome mimetics and exosome trafficking. However, their presence is not 
necessary after release of the vesicles occurs. Thus, association of these proteins in exosome mimetics is 
not required for the drug delivery process [46]. Key proteins are described below:
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3.2.1 Tetraspanins
Cluster of differentiation (CD)9, CD63, CD81 and CD82 are exosomal transmembrane proteins, and also 
known as tetraspanins. Often, they are used as markers for exosomes [47–49]. Some of these 
tetraspanins are detected in high concentrations in exosomes compared to their parent cells. For 
instance, exosomes derived from DCs are found enriched in CD9 compared to cells they originate from 
[50]. Whereas exosomes arising from B lymphocytes are found heavily enriched in CD37, CD63, CD81 
and CD82 [49,51]. While CD81 is specifically present in high levels in trophoblast-derived exosomes, in 
contrast, CD63 is not detected in both exosomes or their parent cells [52]. 
The relatively small size of tetraspanins (20–30 kDa) and their limited interaction between ligand and 
receptor make them difficult to investigate; hence, biochemical or immunological detection is not 
successful [53]. However, total internal reflection fluorescence (TIRF) microscopy, a super resolution 
microscopy,  was used to study the dynamics of tetraspanins CD9 web [54]. Therefore, techniques 
involved with super resolution microscopy and the analysis of tetraspanins dynamics can provide 
essential insights of these molecules function [55]. 
It is believed that tetraspanins have potential functions as therapeutic tools in the drug  delivery field, 
due to their role as mediators of fusion, cell migration, cell to cell adhesion and signalling [56]. 
Furthermore, they have a fundamental action in ESCRT-independent pathways, particularly with regard 
to the differences between cell types [49]. For instance, in mice with CD9 deficiency, exosome 
production is affected in bone marrow DCs (BMDCs)[57]. In contrast, the deficiency of CD81 in 
lymphocytes does not affect the production of exosomes [58]. In addition, tertraspanins are involved in 
cargo selection, targeting and uptake, and antigen presentation [49]. CD9, CD63, CD81 and CD82 
tetraspanins also play a role in DCs migration [47,48]. These tetraspanins are considered as organisers 
for APCs include DCs, monocytes, and B cells. They are also involved in regulating efficient immune 
responses [59]. 
3.2.2 Adhesion molecules 3.2.2.1 Integrins
By referring to the ExoCarta database, integrins are classified as exosomal proteins, that have been 
found abundantly, specifically in tumour and immune cell-derived exosomes [60]. They are found as 
heterodimers (α and β subunits) and 24 different heterodimers have been observed in vertebrates. β1, 
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β2 integrins, and αv containing integrins represent the largest categories. They work as adhesion 
molecules and organise binding of cells to the extracellular matrix (ECM) [61,62]. In exosomes, these 
integrins play a role in guiding the vesicles to fuse to the desired target cells [63]. Therefore, integrin 
involvement in mimetics of exosomes may increase the possibility of interactions between exosomes 
and the ECM, but also induce their delivery possibilities [41]. 3.2.2.2 Thrombospondin 1 and 2
Thrombospondin 1 is classified as an adhesion molecule, found in exosomes that may be incorporated in 
exosome mimetics. This adhesion molecule has been demonstrated particularly in healthy volunteers’ 
physiological fluids such as urine and saliva [64–67]. Additionally, patients with cancer in general, show 
exosomes that are found to contain thrombospondin 1 and 2 [68,69].3.2.2.3 Intercellular Adhesion Molecules (ICAMs)
The intercellular adhesion molecules (ICAMs) family is considered one of the adhesion molecule classes 
involved in cell adhesion and leukocyte trans-endothelial migration [70]. ICAM-1 and ICAM-3 have been 
demonstrated in exosomes derived from immune cells [51,71–74]. They are thought to work as 
significant mediators during immune responses. For instance, ICAM-1 is meant to be a ligand for integrin 
αL β2 (lymphocyte function-associated antigen-1 (LFA-1)) and macrophage-1 antigen (Mac-1). Moreover, 
it induces leukocyte adhesion [75]. Interestingly, ICAM-1 is detected abundantly in exosomes derived 
from mature DCs, compared to exosomes derived from immature DCs.  It has been stated that mature 
DC-derived exosomes are more potent than immature DC-derived exosomes to stimulate T cell 
activation in vitro. It has been suggested that mature exosomes enriched with ICAM-1 play a role in 
exosome adhesion to trigger APCs, through priming naive T cells [76]. A follow up study, has revealed 
that exosomes bearing high levels of ICAM-1, trigger stronger immunity responses, in vitro and in vivo. It 
has been demonstrated that the adhesion of exosomes to immune cells is mediated through the 
expression of ICAM-1 on exosomes, and LFA-1 ligand on recipient CD8+ cells in vivo [77]. While ICAM-2 
and ICAM-3, were found to be attached to DC-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN), ICAM-2 on endothelial cells and ICAM-3 on T lymphocytes, were found to contribute 
to trans-endothelial migration of DCs and the formation of DCs-T cell synapse (C), respectively [78]. In 
terms of exosomes, ICAM roles are still under examination [41]. 
Page 9 of 55
https://mc04.manuscriptcentral.com/fs-tde
Therapeutic Delivery
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Version: 6th December 2017
Article Body Template
3.2.3 Other membrane proteins
CD55 and CD59, were found to play a role in promoting drug delivery in exosome mimetics. These two 
molecules are derived from different origins such as B cells, DCs, colon-rectal cancer cells, saliva and 
bronchial epithelial cells [65,69,79–81].
Another protein considered to be important is lactadherin (also known as Epidermal Growth Factor 
(EGF)-factor VIII or  Milk Fat Globule factor 8 protein (MFG-E8)) [50]. Lactadherin has specifically been 
found in immune cell-derived exosomes and fibroblasts [50,82–84]. It has been found that the C1C2 
domain of lactadherin has an effect on antigen expressing tumours when combined with a protein of 
interest. For instance, a vaccine consisting of chicken ovalbumin (OVA) encoded in a DNA vector bound 
to the C1C2 domain, showed slower growth in tumours expressing OVA antigen, compared to 
vaccination with OVA vector only [85–87]. 
3.3 Nucleic Acid
Micro ribonucleic acid (miRNA) and messenger RNAs (mRNA), are significant components of exosomes 
in healthy and disease conditions. These exosomal RNAs, are transferred between cells, either encoding 
protein or silencing targeted genes. These findings explain the contribution of exosomal RNA to several 
biological processes such as immune system activation or inhibition, cancer progression, angiogenesis, 
viral infections and immunological synapses formation [88–91]. Other types of RNA, have been found in 
exosomes, such as viral RNAs, Y-RNAs, fragments of transfer (tRNAs), small nuclear RNA, small nucleolar 
RNA, piwi-interacting (pi-RNAs), and long non-coding (lncRNAs). Around 764 miRNAs, 1639 mRNAs have 
been discovered in these nanovesicles arising from different tissues [92–95]. The loading mechanism of  
these RNA species into exosomes are not fully known [29]. 
Exosomal cargo can be investigated using multiple protocols including Western blot analysis and 
Bradford assays for protein identification and quantification, respectively. Exosomal RNA can also be 
recovered using a RNA isolation Kit and the isolated RNA analysed by Reverse Transcription and 
Quantitative Real-Time PCR (qRT-PCR). Finally small RNA libraries can be prepared and  exosomal RNAs 
sequenced [96].
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Exosomes originate from different cell types and can be present in biological fluids such as urine, breast 
milk, synovial fluid, blood, saliva and amniotic fluid [97]. For this reason, exosomes appear to play a 
significant role in cell-cell communication and initiate important physiological responses such as 
coagulation, angiogenesis, immune system activation or suppression and inflammation. Exosomes were 
initially found to be involved in the maturation cycle of the cell to remove unnecessary proteins [98]. 
Exosome functions also vary based on their origin or parent cell. Platelet-derived exosomes, are involved 
in the inflammation reaction due to the presence of prostaglandin in these exosomes [99].  
Furthermore, in cancer, exosomes develop a tumour microenvironment through delivering mutated 
genetic material and misfolded proteins [100–103]. 
5. Cancer-derived exosomes
The main areas of focus of cancer-derived exosomes in cancer has been in disease progression, 
diagnostics and therapeutic applications. These are outlined below in more detail:5.1 The role of cancer-derived exosomes in disease progression  
In pathological conditions, cancer stem cells  and mesenchymal stem cells are considered as tumour 
microenvironment regulators, therefore, it is believed that their secretion of  exosomes contributes to 
their regulatory function through cell-cell communication [104]. It has also been found that exosomes 
exert an endocrine effect which means that they can migrate to distant cells and induce cell 
transformation. Hence, tumour growth and cell progression are regulated by cancer cell derived 
exosomes which are considered  tissue modulators. Exosomes released from cancer cells have been 
named ‘’oncosomes’’ due to their ability to travel to distant tissues, develop a pre-metastatic niche, and 
stimulate the migration of tumour cells to conditioned tumour microenvironment [105]. For instance, a 
recent study was carried out by Kumar et al. to reveal the pathogenesis process of acute myeloid 
leukaemia (AML). It has been demonstrated that AML derived exosomes induce DKK1 expression in 
bone marrow stromal cells which suppress normal haematopoiesis and osteogenesis, causing loss of 
osteoblasts. Moreover, tumour derived exosomes cause downregulation of supporting genes of 
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hematopoietic stem cells in BM such as C-X-C motif chemokine ligand 12 (CXCL12), kit ligand (KITL) and 
insulin like growth factor 1 (IGF1), which affect the normal haematopoiesis process [106]. 
In normal situations, the immune system is considered to induce apoptosis and suppress aggressive 
progression. For instance, exosomes secreted from APCs induce the expression of major 
histocompatibility complex (MHC) class I and II on the cell surface, which are followed by specific 
immune reactions through the activation of CD8+ and CD4+ [63,107,108]. While in the case of tumour 
progression, immunosuppression is promoted by cancer-derived exosomes through stimulation of the 
production of suppressor cells, or inhibition of cytotoxic T cell production, natural killer cells (NK) and 
APCs [109]. It has to be noted that DCs are considered professional APCs due to their antigen presenting 
capacity, and their ability to prime and initiate T cells responses [110]. Furthermore, It has been found 
that the maturation process of DCs is inhibited due to their uptake of cancer-derived exosomes [111]. It 
has been reported earlier by Valenti et al. that DCs production is affected by tumour-derived exosomes 
which has resulted in low expression of DCs co-stimulator molecules and secretion of inhibitory 
cytokines, that is caused directly by insufficient priming of T-cell by DCs [112]. 
Tumour cells escape being destructed by  cytotoxic T cells through low expression of MHC-I, however, 
tumour cells are still recognised by NKs [113]. In order to avoid destruction by NKs, a study was carried 
out by Hedlund et al. who demonstrated that NK (Group 2D, member D) (NKG2D) receptor was found to 
be expressed on exosomes which causes an impairment of NKG2D mediated NK-cell cytotoxicity, 
resulting in immune evasion of leukaemia /lymphoma cells [114].
5.1.1 Immune system activation and suppression
Cancer progression is induced through several biological processes including the activation of immune 
suppressor cells, defective antigen presentation, and the induction of T-cell apoptosis which results in 
insufficient immune response [113].
Several studies have shown that T-cells can be activated directly and indirectly by exosomes [115–117]. 
For instance, in direct activation, exosomes produced by APCs such as DCs exhibit MHC class I and II 
peptides, co-stimulators and adhesion molecules. The presence of these molecules on exosome surfaces 
facilitate the activation of T cells (CD8+ and CD4+) in order to induce a prominent immunogenic 
response [63,107,118]. Indirectly, DCs transduced with tumour peptides produce immunogenic 
exosomes that cause a significant anti-tumour response through activation of T cells (CD8+) [63]. 
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Furthermore, NK cells and macrophages can be activated by the presence of heat shock protein 70  
(HSP70) on the exosomal surface [119]. It has been found that exosomes released from cancer cells 
subjected to heat stress induce stronger antitumour immune response compared to non-heat stressed 
cancer cell-derived exosomes [120].   Exosomes derived from immune cells (e.g. NK) have an immune 
function. NK-derived exosomes contain perforin molecules which are known as effector molecules. It 
has been suggested that perforin molecules can trigger cell death through exosome uptake by the target 
cells and consequent release of perforin inside the target cell. These exosomes work as mediators of 
anti-tumour activities [121].  
In contrast, tumour-derived exosomes can work as immune system suppressants [108]. Exosomes 
modulate immune system responses through several processes such as changing the gene expression 
and the function of human regulatory T cells (Treg) through signalling with cell surface receptors [122]. 
Also, It has been noted that nasopharyngeal carcinoma (NPC) or tumour-derived exosomes modulate 
the phenotype of Treg and induce their suppressive function [123,124].  Furthermore, tumour-derived 
exosomes have been found to induce the production of prostaglandin E2, IL6, and TGF-β of MDSCs 
resulting in formation of a solid immunosuppressive environment [125,126]. Another example is 
demonstrated by NK cells that can be suppressed by tumour-derived exosomes expressing a NKG2D 
receptor [127]. Moreover, in a recent study, circulating plasma exosomes of patients with AML were 
found to be carrying immunosuppressive antigens and inhibitory molecules that suppress activated 
immune cells and interfere with adoptive cell therapy (ACT). This was investigated through the 
administration of activated NK cells into AML patients with pre-therapy plasma. This resulted in 
immunological dysfunction which included NK cell deficiency and suppressed activity, high levels of 
regulatory T cells, and dysregulated cytokines which could result in leukemia relapse [128]. 
Additionally, T-cell apoptosis can be induced by released exosomes expressing Fas Ligand (FasL) [129]. In 
the murine system, the differentiation process of DCs can be affected due to the presence of cancer 
exosomes that induce the expression of interleukin-6 (IL-6) by parent cells [130]. Furthermore, infected 
cells release exosomes with pathogenic antigens which generate an immune response against specific 
microbes [108]. 
Tumour-derived exosomes can also play an indirect role in favour of disease progression through 
influencing monocytes and macrophages to exhibit immunosuppressive molecules such as dysregulated 
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cytokines. For instance, in chronic lymphocytic leukaemia (CLL), tumour-derived exosomes contain a 
noncoding Y RNA, an exosomal microRNA called hY4. This hY4 were found to possess a pro-tumourgenic 
effect that was able to induce the production of phenotypically CLL associated monocytes expressing 
programmed cell death ligand 1 (PD-L1). This study has indicated that the transfer of tumour-derived 
exosomes or hY4 to monocytes, induced inflammatory related cancer reactions and  immune escape via 
the expression PD-L1 [131]. Moreover, it has been found that gastric cancer (GC)-derived exosomes 
enable monocytes to produce tumour associated macrophages (TAMs) expressing programmed cell 
death (PD1) with M2-like surface phenotypical characteristics that inhibit antitumour immunity and 
induce tumour progression  [132].
EVs/exosomes released from immune cells, are considered factors that facilitate the metastasis of 
hepatocellular carcinoma (HCC). The process starts through a long non-coding RNAs (lncRNAs) shuttle 
between immune cells and human liver cancer cell-derived EVs/ exosomes which resulted in metastatic 
phenotypical acquisition in the immune cells mediated through their EVs [133].
5.1.2 Angiogenesis
Tumour-derived exosomes are found to be strongly involved in the angiogenesis process through their 
role in cell-cell communication, and their genetic and proteomic cargo that may induce up- or down-
regulation of significant proteins and genes in normal tissue, enhance tube formation and increase cell 
proliferation.  For instance, tumour cells and human renal cancer stem cells (CSCs) release exosomes 
that may trigger angiogenesis and promote a pre-metastatic niche. While exosomes released from 
human renal CSCs expressing mesenchymal stem cell marker CD105, were found to be CD105+ 
exosomes. These CD105+CSCs secrete exosomes bearing 24 miRNAs that were found to be responsible 
for regulating significant biological processes such as transcription, metabolic processes, proliferation, 
nucleic acid binding and cell adhesion molecules. Also, exosomes specifically secreted from CD105 
expressing CSCs contain pro-angiogeneic genes such as vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), angiopoietin1, ephrin A3 (EFNA3), matrix metalloproteinase 2 (MMP-2), 
and MMP-9 and growth factors. Conversely, exosomes derived from tumour cells that are not 
expressing CD105 were found to be less effective in promoting angiogenesis than exosomes released 
from CD105+CSCs [134].
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Another example are CD90+ liver cancer cell-derived exosomes, found to promote tube formation and 
cell adhesion. It has been demonstrated that CD90+ cancer cells contain high levels of lncRNA H19 which 
is released through their exosomes. lncRNA H19 was found to modulate endothelial cell phenotype with 
more angiogenic properties and to induce the adhesion of CD90+ cells to endothelial cells through 
overexpression of ICAM-1 in human umbilical vein endothelial cells (HUVECs) [135]. 
Hypoxia was found to favour the angiogenesis process through secreting pro-angiogenic factors and 
inducing overexpression of exosomes cargo, compared to cancer cells growing in non-hypoxic 
conditions. For instance, miRNA profiles of the human leukaemia cell line K562 and their exosomes 
change under hypoxia. Following miRNA array analysis, exosomes isolated from K562 cells under 
hypoxic conditions, were found to contain high levels of miR-210. This increased secretion of miR-210 
containing exosomes induced angiogenesis through promoting tube formation after co-culturing them 
with HUVECs by downregulating an anti-angiogenic factor called EFNA3 [136]. In a similar study carried 
out by Umezu et al., multiple myeloma (MM) cells were cultivated continuously under chronic hypoxic 
conditions to produce hypoxia-resistant MM (HR-MM) cells. These cells were found to produce high 
amounts of exosomes with upregulated miR135b. This exosomal miR135b was demonstrated to 
promote angiogenesis and subsequent tube formation via a HIF-FIH signalling pathway [137]. Another 
recent study on the hypoxia effect on promoting angiogenesis was carried out by Hsu et al., focusing on 
hypoxic lung cancer cell-derived exosomes. These cancer-derived exosomes were found to express 
highly upregulated miR-23a, which was found to work as a suppressor for prolyl hydroxylase 1 and 2 
(PHD1 and 2). This was followed by hypoxia-inducible factor-1 α (HIF-1 α) accumulation in endothelial 
cells. Consequently, angiogenesis was found to be enhanced [138]. 
Signalling proteins were found to be involved in disease progression, angiogenesis and metastasis. For 
instance, WNT5A is a non-canonic signalling protein that has been found to promote malignant 
melanoma progression. Melanoma tumours expressing high levels of WNT5A were found to be 
associated with distant metastasis and lack of prognosis [139]. The role of WNT5A in cancer progression 
was further studied by Ekström et al. who revealed that WNT5A signalling promotes the release of Ca2+-
dependent exosomes that express immunomodulatory and pro-angiogenic factors such as IL-6, VEGF 
and MMP2 in melanoma cells [140]. An interesting study was performed by Gopal et al. on exosomes 
released by oncogenic epithelial cells undergoing epithelial mesenchymal transition (EMT). These cells 
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were found to produce exosomes expressing Rac1, a signalling protein and p21-activated kinase-2 
(PAK2), an Rac1 target. These Rac1/PAK2 expressing exosomes were able to communicate with 2F-2B 
endothelial cells and trigger angiogenesis by inducing cell motility, vessels formation and extended 
formed vessel length. In contrast, pre-treating endothelial cells with inhibitors of PAK resulted in 
reduction in the tube formation, length and branching of endothelial cells [141]. 
Some signalling proteins work as regulatory carriers for microRNAs. For example, signal transducer and 
activator of transcription 3 (STAT3) is a signalling protein that contributes to angiogenesis by regulating 
exosomal miR-21. This was investigated by Liu et al. by isolating exosomes from cigarette smoke extract 
(CSE)-transformed human bronchial epithelial (HBE) cells, followed by incubating these exosomes with 
normal HBE cells.  These (CSE) transformed (HBE) cells-derived exosomes contained STAT3 regulated 
miR-21 which was transferred to normal HBE cells and modulated their phenotype. This was followed by 
high expression of VEGF, induced tube formation and increased relative tube length [142].
Another study performed by Chan et al. studied angiogenesis by identifying dysregulated proteins of 
nasopharyngeal carcinoma cell (NPC)-derived exosomes, and their following outcomes. Quantitative 
proteomics was used with NPC C666-1 derived exosomes to distinguish downregulated proteins with 
angiogenic properties. It was found that ICAM-1 and CD44 variant isoform 5 (CD44v5) were upregulated 
In C666-1 derived exosomes. Conversely, thrombospondin-1 (TSP-1), an angio-suppressive protein was 
found to be downregulated. Furthermore, HUVECs protein expressions of ICAM-1 and TSP-1 were found 
to be altered after internalisation of C666-1 exosomes. Consequently, angiogenesis was stimulated 
through induced tube formation, migration and invasion  [143].
A recent study was carried out by Tang et al. to investigate ovarian cancer cell pro-angiogenic factors 
that facilitate tumour spreading. In this study, it was demonstrated that exosomes released by ovarian 
cancer cells were found to express high levels of soluble E-cadherin (sE-cad). These sE-cad+ exosomes 
were found to promote angiogenesis in HUVECs, stimulate migration and tube formation [144]. 
Exosomes derived from the pancreatic cancer cell line PK-45H were found to promote angiogenesis 
through activating the expression of various genes in HUVECs in vitro. However, the role of PK-45H cell-
derived exosomes in the development of the tumour microenvironment is still unknown. In HUVECs,  it 
has been found that the phosphorylation process of Akt and ERK1/2 signalling pathway molecules , an 
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upstream regulator, and tube formation were induced via dynamin-dependent endocytosis after the 
internalisation of PK-45H cell-derived exosomes [145].
Another study was performed on glioma cell-derived exosomes to study their role in angiogenesis.  A172 
glioma cells were found express high levels of lncRNA POU3F3; consequently, their derived exosomes 
were enriched with lncRNA POU3F3. To investigate these exosomes, they were cultured with human 
brain microvascular endothelial cells (HBMECs). This culture resulted in high expression levels of lncRNA 
POU3F3 in HBMECs, in addition to high protein expression of basic (bFGF), bFGF receptor (bFGFR), VEGF 
factor A (VEGFA), and new blood vessels formation. This study also indicated that A172 cell-derived 
exosomes can induce angiogenesis, tube formation, cell migration and proliferation [146].
Most of these above mentioned studies have suggested the use of cancer-derived exosomes and their 
upregulated genes and protein as therapeutic approaches in the future to suppress angiogenesis and 
prevent cancer progression.
5.2 Cancer-derived exosomes as diagnostic and prognostic tools in cancer
5.2.1 Proteomic Analysis
Cancer cell-derived exosomes are enriched with a  distinctive amount of nucleic acids (mRNA and 
miRNA) and proteins, which are different in content from exosomes derived from healthy normal cells 
[147]. In cancer studies, proteomic analysis is essential, in order to study the consequences of the 
detection or loss of specific proteins, their significant expression, or their presence levels. For instance, 
exosomes can be used as a detection tool of different types of cancer such as prostate, breast and 
ovarian cancers. In ovarian cancers, Claudin protein is a specific protein, that is shed from the cancer 
cells. This protein has been detected in ovarian cancer cell-derived exosomes, which are not detectable 
in exosomes derived from healthy individuals. Furthermore, Claudin can be detected in blood-derived 
exosomes from ovarian cancer patients. Therefore, the analysis of exosomes containing Claudin, 
released in the peripheral circulation of ovarian cancer patients can be used in blood screening for 
ovarian cancer biomarkers [148]. Proteomic analysis of tumour-derived exosomes, has revealed that 
exosomes isolated from tumour origin, expressed distinctive integrins on their surface. α6β4 and αvβ5, 
were found to be associated with lung metastasis, and liver metastasis, respectively. Hence, organo-
tropic metastasis can be determined using tumour exosome integrins [149]. 
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In the urinary tract, different levels of expression of exosomal proteins in urine samples from patients 
with bladder cancer can be distinguished from other conditions. For example, in one study, the 
concentration of these proteins was quantified using Liquid Chromatography Multiple-Reaction-
Monitoring Mass Spectrometry (LC-MRM/MS) and twenty-four proteins showed a significant difference 
in the concentration between hernia and bladder cancer patients. Also, It has been observed that 
tumour-associated calcium-signal transducer 2 (TACSTD2) is a significant protein that can be used for 
non-invasive diagnostic purposes in bladder cancer [150]. In breast cancer patients compared to healthy 
individuals, a significant loss of SH3GL2 and MFN2 proteins has been detected, which are traceable in 
serum-derived exosomes in healthy women. These proteins, were found to be responsible for the 
regulation of mitochondrial function. Potentially, the loss of these proteins can be used as an indicator 
for primary tumour growth, progression, and metastasis [151]. Moreover, fibronectin (FN) has been 
demonstrated in the plasma of breast cancer patients of all stages. Therefore, the detection of early 
breast cancer can be monitored through liquid biopsy to detect FN [152]. Another breast cancer study 
was carried out by Moon et al. which revealed a novel biomarker called - developmental endothelial 
locus-1 protein (Del-1) that could be used for early detection of breast cancer [153]. In the case of 
prostate cancer (PC), high expression of prostate specific antigen (PSA) and biomarkers was observed on 
secreted exosomes, which was induced by the acidity of tumour microenvironment [154].
Interestingly, a recent study performed by Sun et al. investigated the exosomal proteomes in saliva and 
serum samples of lung cancer patients. It was observed after liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis that 11 potential proteins were detected in both samples.  This result 
indicates that body fluid-derived exosomes expressed similar cancer related molecules [155].
Another example of proteomic analysis that shows usefulness has been demonstrated on three lines of 
hepatocellular carcinoma (HCC), which is known as a cancer of high malignancy. It was found that HCC 
cell-derived exosomes contain a high number of factors of pro-tumourigenic RNAs and proteins, such as 
MET proto-oncogene, S100 family members and caveolins. These factors are considered metastasis 
causing factors, due to their influence on normal hepatocyte mobility and invasion. Potentially, these 
factors facilitate the tracking of the metastasis process [156].
Finally, in an Acute leukaemia model, Jurkat cell-derived exosomes have been found to be specifically 
enriched with 14 membrane proteins. Valosin-containing protein (VCP) is the most abundant and is a 
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membrane ATPase, that is responsible for endoplasmic reticulum (ER) homeostasis and ubiquitination, 
which are thought to be important in metastasis. This protein also serves as a prognostic biomarker in 
gastric carcinoma [157]. 
5.2.2 Nucleic Acid analysis
Serum, plasma and urine samples have been used to investigate cancer patients’ conditions through the 
analysis of cancer related biological media-derived exosomes. Such exosomal analysis provides a non-
invasive way to monitor and diagnose different types of diseases instead of organ biopsies that have 
been traditionally used with cancer patients.  Consequently, if liquid biopsy were applied as a primary 
analysis to analyse the circulating exosome; this will minimize the aggressive techniques that are usually 
taken with cancer patients in future studies [112,123].
Cancer can be investigated and monitor d through characteristic expression of exosomal RNA (miRNA 
and mRNA), which is  considered a significant diagnostic and prognostic tool in cancer diseases [3].  
Therefore, the different types of RNAs in exosomes could provide a unique signature of the original cells 
which can be useful for diagnostic purposes of various diseases. Chen et al. (2008) identified specific 
expression patterns of exosome-derived miRNAs for lung and colorectal cancers providing evidence that 
exosomes can be used as fingerprints of various diseases [158]. Michell et al. (2008) reported the 
presence of serum levels of exosomes that are loaded with miR-141, a miRNA expressed in prostate 
cancer which can be used as diagnostic markers for this type of cancer [159]. In one significant 
investigation into prostate cancer, urine samples were collected to detect any phenotypical changes 
that could reveal the status of the patients. The main two genes detected in the transcript of exosomal 
mRNA were PCA-3, and TMPRSS2:ERG. These genes were analysed among untreated prostate cancer 
patients at different stages. It was found that TMPRSS2:ERG was detected in patients with high-risk 
tumours, while PCA-3 gene was detected in all untreated patients. These genes act as diagnostic and 
prognostic biomarkers for prostate cancer [160]. The miRNA cargos in the circulating exosomes are 
representative of those expressed in the originating tumour, enabling the opportunity of early diagnosis 
of different tumours and metastases. These diagnostic markers in the exosomes could be a by-product 
of the metabolic process in cancer cells or they could be a signalling process as part of cancer cell 
metastasis.
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Several companies have initiated the development of diagnostic tools based on exosome content in 
specific samples. The Carisome® Prostate cMV 1.0 test is an example of such a diagnostic kit lunched by 
Caris Life Sciences in 2010 which is a sensitive diagnostic tool for prostate cancer based on the analysis 
of specific exosomal proteins [161]
Another study examining bladder cancer patients found that a significant number of microRNAs were 
upregulated in the urine and the white blood cells (WBCs) of the cancer patients. In contrast, no 
upregulation of microRNAs was detected in blood samples of the same patient. This indicates that 
microRNAs vary according to their biological origin. Therefore, urine is considered one of the biological 
fluids that should be analysed in cases of urinary tract related-cancers [162]. On the other hand, 
serum/blood analyses can provide better information for patients with other types of cancers. For 
instance, overexpression of miR-21 was detected in breast cancer-derived exosomes, or in the systemic 
circulation of breast cancer patients [163]. Furthermore, in non-small lung carcinoma (NSCLC), six 
microRNAs were demonstrated with significant abundancy in serum samples from NSCLC patients. Due 
to the easy access and the stability of exosomal miRNA, these identified microRNA are considered 
promising biomarkers for future screenings [164].
The analysis of mRNA and miRNA has also been used for prognostic purposes. For example, in human 
oesophageal squamous cell carcinoma (ESCC), exosomes isolated from serum samples of ESCC patients 
has shown upregulation of miR-21 gene compared to patients with benign disease. This gene is 
associated with tumour progression and invasiveness [165]. 
Differentiation between cancer types or chronic inflammation of the same organ can also be detected 
by nucleic acids analysis. For instance,  patients with lung adenocarcinoma and lung granulomas can be 
differentiated through four miRNA, detected in their plasma samples [166]. Moreover, exosomes 
derived from the plasma of pancreatic ductal adenocarcinoma (PDAC) patients have shown high levels 
of miRNA-10b compared to chronic pancreatitis patients or healthy individuals [167]. Another study has 
also confirmed that high exosomal expression of miR-10b and miR-30c are considered superior 
diagnostic markers to exosomal glypican-1 (GPC1) for PDAC patients [168]. In contrast, GPC1 is 
considered as a specific diagnostic biomarker in colorectal cancer (CRC) due to high expression levels in 
tissues and plasma derived exosomes. Moreover, low expression of miR-96-5p and miR-149 levels in 
plasma was also considered as specific marker of CRC [169]. 
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6. Therapeutic applications of cancer-derived exosomes 
Due to exosome involvement in cancer progression and metastasis and their excessive secretion, one 
therapeutic approach has been applied to control or stop the secretion process. It has been found that 
the concentration of intracellular calcium is an important factor for exosome secretion. Dimethyl 
amiloride (DMA), an inhibitor for calcium channels, has been used to prevent exosome synthesis [125].  
It has been observed that the blockage of Rab27a, one of the Rab GTPases that regulate the secretion of 
exosomes resulted in reduction of primary 4T1 breast cancer growth and subsequent lung metastasis. 
Interestingly, 4T1 growth tumour requires mobilisation of neutrophils in order to metastasise which has 
been found to be induced by Rab27a-dependent secretion of exosomes along with specific cytokines 
and/or metalloproteinases  [170]. It has been found that pre-miRNA and siRNA were used to target 
YKT6, which is a SNARE protein that is involved in the process of exosome production and release. As a 
result, inhibition of YKT6 expression was observed, which had an impact on exosome synthesis and was 
reduced by 80.9%. The lower the YKT6 expression, the higher the chance of survival in NSCLC patients 
[171]. 
Exosomes utilise a unique advantage of gaining entry to cells similar to the way viruses do. As a result of 
this transfection efficiency of exosomes, they can be used as a novel delivery system for gene therapy 
[172]. Moreover, RNA-containing exosomes derived from cells can serve as functional genetic 
biomarkers, which can be used for disease diagnosis [173]. These therapeutic and diagnostic 
characteristics are termed theranostics in the field of nanomedicine [174]. In order to obtain an effective 
exosome-based delivery system, different components must be carefully chosen and controlled in order 
to achieve the correct functionality and efficacy. This starts with the optimal choice of the donor cell 
type from which the exosomes will be collected. These exosomes must be non-immunogenic to prevent 
any inflammatory response after administration and must be stable enough to deliver their drug cargo 
to the desired site of action. Different cell types have been used as exosome factories including HeLa, 
HEK-293, B16-F10, B16-BL6 and B16-F1 cell types [175].
Moreover, exosomes should be able to carry a sufficient amount of the intended therapeutic cargo to 
qualify as a drug delivery system. For efficient application of the exosomes as a delivery system, there 
should be an efficient method to load these exosomes with the therapeutic cargo. Several approaches 
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have been applied to load exosomes with therapeutic agents including classical cell transfection 
methods like electroporation, simple incubation and the use of chemical transfection reagents, but 
more sophisticated methods like transfection or activation of the exosome donor cell have also been 
investigated [175]. 
Table 1 provides a snapshot of cell line-derived exosome applications. Based on the studies mentioned 
in this table, cancer cell line-derived exosomes play a major role in cell differentiation, proliferation and 
tumour metastasis. Other studies represent the efficiency of these exosomes as biomarkers for 
diagnosis and their potential therapeutic approaches. 
Table 1 Summary of applications of cancer-derived exosomes.
Cancer Cell lines (Human) Role of cancer cell line-derived 
exosomes 
Multiple Myeloma (MM) U266, MM1S and OPM2
derived from MM patients 
(Human)
Involved in osteoclast differentiation 
[176].
Burkitt’s Lymphoma DG75, sublines (LMP1 
transfected and EBV infected) 
(Human) 
Stimulate proliferation and 
differentiation of B-cells to a 
different cell class called 
plasmablasts [177]
Breast MCF-7 and MDA-MB-231 
derived from breast cancer 
patients (Human)
Play an important role in tumour 
metastasis [178].  
Ovarian UL-1, UL-2, UL-3, UL-6, UL-B, 
and UL-O. UL-2 and UL-3 were 
derived from hereditary ovarian 
cancers, while UL-1, UL-6, UL-B, 
and UL-O were derived from 
spontaneous cancers (Human)
These exosomes contain a distinct 
microRNA profile that act as 
biomarkers of ovarian cancer and 
are used in diagnosis [173].
Metastatic melanoma 
(monocyte derived DCS)
Manufactured from peripheral 
blood mononuclear cells 
(PBMCs)-DCS cell line (Human)
Patients with metastatic melanoma 
vaccinated with autologous 
dendritic cell-derived exosomes 
(DEX) This clinical trial, has shown 
that exosome production can be 
large scale. In addition  no toxicity 
associated with exosome 
administration has been observed 
[179].
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Non-small lung carcinoma 
(NSCLC)
Manufactured from PBMCs-DCS 
cell line (Human)
Patients with advanced NSCLC 
administered autologous DCS-
derived exosomes by vaccination 
(DEX). As a result, activation of the 
immune system of patients has 
been observed. Moreover, disease 
stability was observed in some 
patients [180]. 
Colorectal SW480 (HLA-A2+CEA+) and 
LoVo (HLA-A2–CEA+) (Human)
Patients with colorectal cancer 
administered with autologous 
ascites cell-derived exosomes (AEX) 
combined with granulocyte–
macrophage colony stimulating 
factor (GM-CSF) [181]
Prostate cancer (PC)
22Rv1, PC-3, LNCaP, and 
WPMY1 cell lines (Human PC 
cell lines)
Exosomes derived from prostate 
cancer cells causing down-
regulation of NKG2D expression on 
NK cells and CD8+ T cells which in 
turn lead to suppression of  the 
immune system and increase in the 
growth of tumours [182]
6.1 Use of exosomes to deliver RNA 
Gene therapy is a technique that uses specific types of nucleic acids delivered by a particular delivery 
system by which an abnormal gene is replaced with a normal one to correct disease manifestation or to 
suppress the function of an overexpressed gene [183]. Exosomes have been postulated to serve as a 
potent gene delivery system as a result of their nanoscale properties along with their function of 
shuttling RNA between cells, which gives them an intrinsic role in endogenous gene transfer in both 
biological and pathological settings [184–186]. 
Several groups have explored this potential. Akao et al. (2011) assessed the use of exosomes as a 
delivery system for RNA. In their work, human monocytic leukaemia THP-1 cells were transfected with 
chemically-modified miR-143 RNA and investigated for their ability to suppress tumour growth [187]. 
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Kogure et al. (2011) investigated the delivery function of exosomes for miRNA communication between 
cells using exosomes derived from HCC. By analysing the contents of the HCC cell-derived exosomes to 
identify potential targets, transforming growth factor β activated kinase-1 (TAK1) was the most likely 
candidate pathway that could be modulated by these miRNAs. Loss of TAK1 has been implicated in 
hepatocarcinogenesis and the HCC cell-derived exosomes can modulate TAK1 expression and enhance 
transformed cell growth in recipient cells [188]. Moreover, miR-16 of synthetic origin, exerts a 
suppressive effect on the proliferation of 22Rv1, Du145, PPC-1, and PC-3M-luc metastatic prostate 
cancer cell lines through the down-regulation of CDK1 and CDK2 cell cycle genes [189]. In a mouse 
model, the expression of miR-143 suppressed the proliferation of prostate cancer LNCaP and C4-2 cell 
lines through the inhibition of extracellular signal-regulated kinase-5 (ERK5) [190].  Another example 
was observed in breast cancer where it was found that enhanced migration and invasion processes and 
cisplatin drug resistance, were associated with the downregulation of miR-134. While miR-134, controls 
STAT5B that controls the expression of HSP90. To overcome this, direct transfection of miR-134 into 
sensitised breast cancer cells Hs578Ts(i)8 showed a reduction in the expression levels of STAT5B, HSP90 
and Bcl-2, reduced cell proliferation, and enhanced apoptosis induced by cisplatin. Delivery of miR-134 
via EV-exosomes caused a reduction in the following:  STAT5B and HSP90 expression levels, cellular 
migration and invasion, and enhanced sensitivity to anti-HSP90 drugs. miR-134 is considered a potential 
biomarker as well as a possible therapeutic approach for breast cancer [191].
Apart from miRNA, siRNA has also been loaded into exosomes. Exosomes derived from human 
embryonic kidney 293 (HEK293) cell and mesenchymal stem cell (MSC) were collected and 
electroporated with PLK-1 siRNA that designed to target the bladder cancer cell line (UMUC3). It was 
found that exosomes of HEK293 bearing PLK-1 siRNA were internalized into UMUC3 bladder cancer cells 
which resulted in knockdown of PLK-1 mRNA and protein expression. Consequently, this knockdown 
induced apoptosis and necrosis of the tumour cell line [192]. 
6.2 Use of exosomes to deliver drugs
One study used celastrol (CEL), a plant derived compound known for its inhibitory function of HSP90 and 
NF-κB activation pathways. Exosomes were loaded with CEL through mixing then administered into mice 
with NSCLC. Two cell lines of NSCLC were used, A549 and H1299. It was found that CEL loaded exosomes 
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inhibited the proliferation of both cell lines and completely suppressed TNFα-induced NF-κB activation, 
upregulated the expression of ER stress chaperones and stimulated apoptosis. In a xenograft model, CEL 
loaded exosomes exhibited an effective anti-tumour response, more so than free CEL, with no systemic 
or gross toxicity observed [193].
It is noteworthy that exosomes provide promising therapeutic delivery for complicated types of cancer 
such as brain cancers, due to their ability to cross the blood brain barrier (BBB) while other therapeutic 
approaches have failed.  An example of this has been demonstrated by encapsulating paclitaxel or 
doxorubicin into brain endothelial-derived exosomes then delivering the drugs to cancer cells in the 
brain. These drug-encapsulated exosomes crossed the BBB efficiently, resulting in smaller U-87 MG 
tumour masses in xenografted zebrafish embryos [194,195]. 
6.3 Use of decorated exosomes with targeting agents to deliver specific cargo 
One therapeutic approach involves attaching targeting peptides or ligands on the surface of exosomes 
to enhance specificity to control the action of the therapeutic cargo and minimise any possible side 
effects. For instance, in breast cancer, Epidermal growth factor receptor (EGFR)-expressing breast 
cancer cells were targeted with modified exosomes containing let-7a miRNA and decorated with the 
transmembrane domain of platelet-derived growth factor receptor (PDGFR), fused to GE11 peptide on 
their surface. These GE11 expressing exosomes containing let-7a miRNA, were administered 
intravenously, and found to bind three times stronger to the tumour cells compared to control 
exosomes. This formulation caused significant inhibition of tumour growth of HCC70, but no repression 
of other genes was detected, during the expression of let-7a [196]. In order to minimize immunogenicity 
and toxicity reactions, exosomes harvested from immature DCs (imDCs) were treated to display Lamp2b 
fused to αγ integrin-specific iRGD peptide on their produced exosomes surface, for tumour targeting 
purposes. Doxorubicin was loaded into these exosomes, to produce (iRGD-Exos-Dox) vesicles. These 
bioengineered exosomes, iRGD-Exos-Dox, were found to be a highly efficient drug delivery vehicle, that 
delivered drug to breast cancer cells which are αγ integrin-positive, with 95% efficacy.  It was also 
observed that iRGD-Exos-Dox caused inhibition in the proliferation of cancer cells, and efficient drug 
delivery in mouse model of breast cancer; with no adverse reactions [197]. 
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Another study, used adeno-associated virus (AAV) vectors, encapsulated into exosomes. These AAV 
associated exosomes, were used in a murine model, and resulted in a significant expression of transgene 
in the cerebellum Purkinje cells [198]. Tumour cells treated with anticancer drugs such as in HCC 
produce exosomes bearing heat shock proteins (HSPs) on their surfaces such as hSP60, HSP70 and 
HSP90. These proteins were found to induce cytotoxic NK cell activity, upregulate  the expression of the 
inhibitory receptor CD94, and downregulate the expression of the activating receptors CD69, NKG2D 
and Nkp44 [199]. In addition,  the HSP location on the exosomes’ surface, determines their anti-tumour 
immune response [200].
6.4 Use of exosomes in immunotherapy
The ability to load exosomes with peptides provides an opportunity to use exosomes in vaccines against 
various types of tumours. DCs are known in cancer immunotherapy as immune system modulators, due 
to their ability to initiate an effective immune response [201–206]. Moreover, exosomes released from 
DCs are found to play a significant role in immune system stimulation. DCs-derived exosomes (DCs-Exo), 
are found to contain the same antigens as their parent cells that are responsible for immune system 
activation in tumour cells. It has been observed that the incorporation of DCs-Exo with cancer cells, 
stimulates an efficient immune response through T-cell activation. DCs-Exo, are therefore considered a 
potential tool in cancer immunotherapy [207,208]. Another application of DCs exosomes uses 
autologous DCs-derived exosomes (DEX). In a phase I trial, vaccination against metastatic melanoma was 
achieved using DEX generated containing functional MHC/peptide complexes capable of promoting T 
cell immune responses and tumour rejection. Fifteen stage III/IV melanoma patients received four 
exosome vaccinations and the evaluations were performed before and two weeks after immunization. 
Following immunization, there was an increase in NK cell number and NKG2D expression was restored in 
NK cells and CD8T cells in some patients. Moreover, there was no grade II toxicity and the maximal 
tolerated dose was achieved indicating the safety of exosome administration [179]. Another phase I 
study was carried out using DEX immunotherapy in patients with advanced NSCLC. In this study, safety 
and efficacy of DEX loaded with MAGE tumour antigens was tested in 13 patients with Stage IIIb and IV 
NSCLC with tumour expression of MAGE-A3 or A4. The study demonstrated the feasibility of large scale 
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production of the DEX vaccine and that the DEX therapy was well-tolerated in patients with advanced 
NSCLC [180] . 
Another example has been demonstrated with autologous ascites-derived exosomes (Aex) combined 
with granulocyte–macrophage colony-stimulating factor (GM-CSF) in a phase I study against colorectal 
cancer (CRC). In this trial, 60–90-nm Aex vesicles were isolated from ascites fluid and immunoassayed. 
Both the diverse immunomodulatory markers of exosomes as well as the ectopic carcinoembryonic 
antigens associated with the tumours that were desired for the immunotherapy were found.  In this 
study, advanced CRC patients were given Aex alone or Aex plus GM-CSF through subcutaneous injection 
weekly for four weeks for each group. Results from this phase I study showed that both treatment 
regimens were safe and well tolerated. However, patients receiving Aex plus GM-CSF, but not Aex alone, 
were found to have a better response through the production of antitumour cytotoxic T lymphocytes 
(CTL). This indicates that the immunotherapy of CRC with Aex in combination with GM-CSF was effective 
and safe with many promising results [181]. In another cancer model, HCC, tumour derived exosomes 
(TEX) containing a wide panel of HCC antigens were used.  HCC bearing mice were treated with TEX-
pulsed DCs, resulting in significant suppression of HCC growth. This was thought to be due to the 
stimulation of the immune system in the tumour microenvironment, which was observed as increased 
numbers of T lymphocytes, high levels of interferon-γ (IFN-γ), low levels of interleukin-10 (IL-10) and low 
expression of tumour growth factor-β (TGF- β) in tumour sites [137].
6.5 Manipulation of parent cells to release desired exosomes
Another therapeutic deployment strategy used to increase exosome efficacy as a delivery system, 
involves treatment of parent cells to produce exosomes with a specified content. For instance, human 
platelets have been treated with aspirin, which results in production of exosomes with less protein 
content without affecting the production levels of exosomes [209]. In another study, fetuin-A, a 
circulating inhibitor of calcification, was internalised into vascular smooth muscle cells (VSMCs). In turn, 
these VSMCs, produced exosomes with calcifying properties, which induce vascular calcification in 
response to environmental calcifying conditions, in vitro [210]. Furthermore, exosome content can be 
modified through transfection of specific proteins or nucleic acids into the parent cells. For example, 
human MSCs transfected with synthetic miR-143, resulted in exosomes formed with miR-143. This 
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synthetic microRNA was then found to be transferred extracellularly from exosomes to osteosarcoma 
cells, which inhibited cancer cell migration, in vitro [211]. 
6.6 Overcoming Cancer Drug Resistance with Exosomes
Exosomes aid the removal of unneeded or harmful molecules from cells. This is useful in understanding 
how exosomes can also eliminate certain introduced drugs from cells which enables drug resistance to 
occur [161]. Thus, exosomes are likely to be an additional route that enables tumour cells to pump out 
different types of chemotherapeutics. Inhibiting the pathways that regulate the secretion of these 
exosomes might be a novel target to reduce drug resistance. For instance, in human melanoma, cisplatin 
resistance is a common issue with targeted tumour cells producing exosomes containing the native form 
of cisplatin. This drug resistance is mainly accompanied by low pH levels which results in impairment of 
drug delivery systems. A proton pump inhibitor (PPI) has been used to neutralise pH levels in the tumour 
microenvironment which results in successful uptake of cisplatin by cancer cells, and inhibition of 
exosome production. In xenograft models, tumours exposed to cisplatin and PPI contained more 
cisplatin compared to tumours treated with cisplatin only. A follow up analysis of plasm showed low 
exosome production levels, and low presence of cisplatin [212]. Similarly, paclitaxel (PTX) a potent 
chemotherapeutic agent has been encapsulated into exosomes (exoPTX) and used to study the efficacy 
of this incorporation on multiple drug resistance (MDR) cancer. It has been shown that the cytotoxicity 
of exoPTX increased more than 50 times in drug resistant MDCSKMDR1 (Pgp+) cells. The administration 
of ExoPTX via the intranasal route into mouse models of LLC-derived pulmonary metastatic tumours, 
resulted in a complete co-localization of exosomes along with cancer cells and significant inhibition of 
lung metastasis progression [213]. In glioblastoma cells resistant to temozolomide (TMZ), anti-miR9 was 
delivered to these cancer cells via mesenchymal stem cells (MSCs) or loaded into exosomes, which 
resulted in downregulation of MDR-1 expression. Moreover, the drug resistance of these cells was 
reversed and re-sensitised to TMZ [214]. 
7. Challenges in Exosome Production
To overcome the following challenges of exosome application in drug delivery: low scalability, donor cell 
unsuitability and low targeting ability, a bioinspired exosome-mimetic nanovesicle were developed by 
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breaking down monocytes or macrophages using serial extrusion, using filters with pore sizes of 10, 5, 
and 1 μm. These nanovesicles share the same characteristics of exosome, but are produced at a higher 
yield (100-fold). Doxorubicin loaded nanovesicles have shown efficacy in delivering drug selectively and 
activate TNF-α-stimulated endothelial cell death in vitro. While in vivo, these bioengineered 
nanovesicles have shown an efficient reduction in tumour growth with no adverse reactions observed 
[215]. Another example, a dual-functional exosome-based superparamagnetic nanoparticle cluster was 
developed. It has been observed that superparamagnetic nanoparticles labelled exosomes (SMNC-EXO) 
display superparamagnetic properties towards an external magnetic field at room temperature, which 
exhibits their efficacy in targeting tumour cells. These engineered vesicles, SMNC-EXO, have shown high 
stability and biocompatibility in fresh murine serum without undesirable side effects. SMNC-EXO 
incorporated with doxorubicin (D-SMNC-EXO) were administered to mice in the presence of a magnetic 
field. It was observed that tumours were significantly  suppressed accompanied by the low expression of 
Bcl-2 and the high expression of caspase-3 [216]. 
To overcome low scale production of exosomes from human cells, bovine milk produce exosomes on 
large scale which can be used as an efficient source of exosomes and a functioning carrier for 
chemotherapeutic/chemo-preventive agents. Drugs incorporated into bovine milk-derived exosomes, 
have shown high efficacy of the encapsulated drug compared with the free form of the drug in 
xenografts of lung cancer in vivo. Furthermore, folate, a tumour targeting ligand, has been found to 
increase cancer-cell targeting when loaded into these exosomes, which result in significant tumour 
reduction. Milk-derived exosomes, exhibit cross-species tolerance with no undesirable immune or 
inflammatory reaction. Use of bovine milk for large scale production of exosomes is considered cost 
effective and a biocompatible replacement of tumour-derived exosomes, due to their versatility and 
their ability to target tumours. A new route for exosome administration has been demonstrated, via the 
oral system and provided a safe and efficient drug delivery system [217]. 
Future Perspective: 
Exosomes represent a hot area of research with many promising results in fighting cancer with agents 
derived from cancer cells. The ability to investigate the exosome contents and investigate the relation 
between these contents and the development of specific disease is a promising diagnostic tool that can 
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be applied in the future. Moreover, the ability to use these exosomes as a delivery system will have 
significant impact on the field of drug delivery in the future. However, more studies and research are 
needed to fully understand all aspects that are related to exosome formation and secretion. 
Developments in other diseases are likely to have significant impact on cancer studies and vice versa. 
This is a field that is worthy of investigation as it expands the portfolio of natural products that can be 
used to treat and diagnose cancer, while also enhancing designer lipid delivery platforms.
In the next 5-10 years, it is envisaged that better large-scale production methods will be necessary, 
which are more likely to be of a mimetic nature as greater characterisation control is needed for 
medicines approval. It is also likely that with greater understanding of the changes encountered with 
disease development, that the diagnostic aspect of exosome-based tools will become more precise, to 
enable better prediction of disease outcomes and monitoring disease progression. This would then lead 
to cheaper and less time-consuming screening options to healthcare services, which in turn would 
provide cost efficiencies, more people to be screened, and with greater accuracy. Overall, in terms of 
both therapeutics and diagnostics, the arsenal available to fight cancer and other major diseases will be 
significantly extended.
Conclusion: 
The field of exosome research has come a long way since their discovery and is progressing at a fast 
rate. Applications are being developed for numerous diseases, not least of all to treat cancer. However, 
a greater understanding is yet to be achieved regarding their characterisation, function, role in disease 
progression, consistency and reproducibility under different conditions, elucidating their signalling 
pathways and mechanisms of action. This will then enable optimal therapeutics, including drug delivery 
approaches, to be developed to expand the “natural products” already in use.
Executive Summary: 
Discovery of exosomes and their production
• Greater understanding of exosome biogenesis has led to providing new targets for management 
of a range of diseases, including cancer.
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Structure and composition of exosomes
• Collation of data on structure and composition of exosomes into two major databases is 
enabling the field to progress at a faster pace through collaboration, rather than separate research 
groups reinventing the wheel.
• Better understanding of exosome lipid and protein contents will aid development of 
therapeutics, but will also impact on other therapeutic delivery products (not based on exosomes but on 
synthetic lipid vesicles).
Cancer-derived exosomes in disease progression, diagnosis and prognosis tools
• The use of cancer-derived exosomes to treat other cancers is revolutionary and providing all 
safety aspects are taken into account, provides an ingenious approach to fight cancer with cancer 
derived components.
Therapeutic applications of cancer-derived exosomes
• The therapeutic applications for exosomes is diverse, particularly as carriers of therapeutic 
cargoes such as proteins, nucleic acids, immune modulators, drugs and natural products.
• Furthermore, understanding how exosomes can be manipulated, will help overcome hurdles 
such as drug resistance. 
Challenges in industrial scale production of exosomes
• Some challenges still need to be addressed, including large-scale production, regulatory aspects 
and safety before exosome therapies will b come mainstream therapeutics. Nevertheless, the 
diagnostics field may proceed at a faster pace, particularly to provide more cost effective screening 
tools.
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Reviewer: 1
Comments to the Author
The authors present  abroad and well written view of cancer=derived exosomes and their role in disease 
as cancer biomarkers and as potential  therapeutic agents. The headlines and subtitles  of this review 
encompass all of the essential aspects of exosomes as potential therapeutic entities.
Comment 1:
The problem is that the text and references are not up to date! The field is moving on very rapidly: The 
review needs to be up-dated in all its aspects. For example, the part dealing with exosome-mediated 
effects on the immune system does not include any of the important molecular, proteomic and 
functional studies in the literature. The authors need to do the literature search and up-date all aspects 
of this work. 
Author response:
• We thank the reviewer for all the comments provided. We have introduced new material 
describing:
• Involvement of CD9 and CD63 in section 2
• LBPA involvement in exosome production  in section 3.1.1
• Lipid distribution and presence in the exosome bilayer in section 3.1.2
• A study on disease progression in section 5.1
• Studies of immunomodulation by exosomes in section 5.1.1
• Proteomic studies of exosomes in section 5.2.1
• Nucleic acid study of exosomes in section 5.2.2
that corresponds to the reviewer’s suggestions and as highlighted in the revised document.  
Comment 2:
As to the format of this review, much quoted data could be put into tables and summarized concisely.
Author response:
• After much consideration, we feel it is better to not summarise the information provided in 
more Tables, as this is a complex subject and providing too many Tables may make it difficult for 
the reader to follow the narrative. 
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Reviewer: 2
Comments to the Author
This manuscript reviews the current knowledge regarding exosome biogenesis and contents, he 
methods used in the study of exosomes and their cargo, how exosomes influence cancer progression 
and their use as tool in the diagnosis and treatment of cancer.
A detailed description of exosomal lipid, protein and nucleic acid cargo is provided. In addition, the 
methods used in proteomic and nucleic acid analysis are described. This manuscript also emphasizes the 
role of exosomes in cancer progression and immunomodulation and how these can be explored in 
cancer diagnosis and treatment. The potential use of exosomes as delivery systems for drugs and in 
immunotherapy are also well described. A specially good feature of this manuscript is that it describes 
the prospective uses of exosomes in cancer study, diagnosis and treatment but also makes reference to 
the current challenges that scientists face when studying exosomes.
The article is well written and elucidative regarding the future prospects for exosomes in cancer 
diagnosis and treatment. Nevertheless, I suggest some the addition of the following information prior to 
its acceptance:
Comment 1:
On section 2, please include a more detailed description of the role of ESCRT complex in cargo sorting 
and of the inherent potential of regulating this complex as well as other proteins involved in exosomes 
biogenesis as a tool for the study of exosomes and in the treatment of cancer.
Author response:
• We thank the reviewer for all the comments provided. We have introduced new material 
(Subheading) describing: the role of ESCRT and exosomal cargo sorting in section 2.1 that 
corresponds to the reviewer’s suggestions and as highlighted in the revised document.  
Comment 2:
On section 3, the authors could briefly mention the protocols used to investigate exosomes cargo and 
highlight the importance of the generated knowledge in cancer diagnosis.
Author response:
• The authors have added more information to the text in section 3.3 as highlighted in the revised 
document.
Page 52 of 55
https://mc04.manuscriptcentral.com/fs-tde
Therapeutic Delivery
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Comment 3:
On section 3.2.1, the authors mention the tetraspanins are very difficult to investigate due to their small 
size and limited ligand-receptor interactions. Was it described any solution to surpass these limitations? 
Are there gold standard and efficient methods to study tetraspanins?
Author response:
• The authors have added more information to the text in section 3.2.1 as highlighted in the 
revised document.
Comment 4:
The section 5.1 mainly focus on immunomodulation mediated by exosomes; other processes involved in 
cancer progression (such as, angiogenesis) should also be described in the context of the association of 
exosomes to their modulation.
Author response:
• The authors have added a  new sub-section on Angiogenesis as described in Section 5.1.2
Comments from the Editor:
1) Please reduce your keywords to 10 or below in your revised manuscript.
Author response:
Corrected
2) Please could you sign your Copyright Assignment form with a real or electronic signature.
Author response:
• Corrected and attached.
3) Thank you for completing the Copyright status table of page 5 of your Author Disclosure form. Please 
could you include you Graphical Abstract in this table.
Author response:
Corrected
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4)  You have indicated that your Figure and Table have been previously published. Please upload the 
permission documents from the Copyright holder of these to prove that you have permission to re-use 
this material. Please also upload the pdfs of the original articles of the material so that we can check the 
correct permissions have been gained.
Author response:
• The figure and the table have been designed for this current manuscript and have not been 
published before. We mistakenly omitted this on the previous form.
5) Please include a Conclusion section to summarize your article. 
Author response:
Completed
6) Thank you for providing an Executive Summary. Please insert headings into this list that correspond 
with the main headings of your article.
Author response:
Completed
7) Please amend the references as per the author guidelines:
a. The Future Science Endnote style can be downloaded from our wesite.
b. Please ensure that the journal abbreviation is presented in italics with full stops following any 
abbreviation:
e.g. Tokuda T, Salem SA, Allsop D et al. Decreased alpha-synuclein in cerebrospinal fluid of aged 
individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1), 162–166 
(2006).
Author response:
Completed
8) Please include reference annotations: up to 8 references should be chosen from your bibliography 
and highlighted as being ‘*’ – of interest, or “**” – of considerable interest, with a brief sentence 
explaining why in each case.
Author response:
Completed
9) Please check that all tables and figure are clearly titled and cited in the text.
Author response:
Checked
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10) Please check that all abbreviations present are commonly used and all are defined in their first 
instance in the manuscript. These should also be redefined in the abstract & figure/table legends if the 
abbreviation is used.
Author response:
Checked
11) During review of your article, I noticed that certain sections of your article are similar to previously 
published work. I have attached a copy the iThenticate report as well as a copy of your article with the 
sections requiring your attention highlighted. Please reword the highlighted sections to avoid any 
copyright issues.
Corrected
12) Therapeutic Delivery offers a selection of post-acceptance services for authors; please indicate when 
you re-submit if you would be interested in any of the following:
a.      Open access publication: Therapeutic Delivery offers an open access option, whereby for a fee, 
articles can be made freely available for all to read. As of 2016, the journal saw over 10-times more 
readers for articles that were freely available, showing a distinct advantage for the open access option. 
Pricing varies by article type; for peer-reviewed content (i.e., Original Research or Review articles), the 
fee is $2,500; for content not reviewed externally (i.e., Editorials or Commentaries), the fee is $850. For 
more information, visit our website here: https://www.future-science-group.com/services/for-
researchers/open-access/. If you are interested in taking this option, please let me know.
We do not wish to take up this offer.
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